Why retatrutide discussion here is more cautious than elsewhere — one year on

Coming back to post #4, because the follow-up matters more than the original answer.

My understanding of retatrutide discussion is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.

Post #15 answers the question as asked. The question underneath it is different.

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

I would rather say I do not know than round it up to an answer.

On post #18 — agreed on the reasoning, with one qualification.

How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does not establish safety, durability, or whether real humans differ from the selected population.

Triple agonism at GLP-1, GIP and glucagon receptors is the defining feature and the glucagon limb is the one people find counter-intuitive. It raises energy expenditure and promotes hepatic fat oxidation, and the incretin limbs offset the glycaemic consequence.

Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.

A modest claim, modestly supported.

Noted, and I have changed what I was going to do on the strength of it.

What I want from this retatrutide discussion thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

I had written a reply contradicting post #91 and deleted it. Here is what survived.

Retatrutide discussion is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.